Adam S Darwich

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1541790/publications.pdf

Version: 2024-02-01

39	1,121	393982	414034
papers	citations	19 h-index	32 g-index

41	41	41	1333
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Why Has Modelâ€Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the Future. Clinical Pharmacology and Therapeutics, 2017, 101, 646-656.	2.3	169
2	Meta-Analysis of the Turnover of Intestinal Epithelia in Preclinical Animal Species and Humans. Drug Metabolism and Disposition, 2014, 42, 2016-2022.	1.7	146
3	Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. Annual Review of Pharmacology and Toxicology, 2021, 61, 225-245.	4.2	74
4	The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery. Pharmaceutical Research, 2015, 32, 3927-3936.	1.7	58
5	IMI â€“ Oral biopharmaceutics tools project â€“ Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results. European Journal of Pharmaceutical Sciences, 2017, 96, 610-625.	1.9	58
6	A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution. Journal of Pharmacy and Pharmacology, 2012, 64, 1008-1024.	1.2	47
7	Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria. European Journal of Pharmaceutical Sciences, 2017, 109, 111-120.	1.9	47
8	Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. British Journal of Clinical Pharmacology, 2012, 74, 774-787.	1.1	45
9	IMI â€“ Oral biopharmaceutics tools project â€“ Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes. European Journal of Pharmaceutical Sciences, 2017, 96, 626-642.	1.9	41
10	IMI â€“ oral biopharmaceutics tools project â€“ evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds. European Journal of Pharmaceutical Sciences, 2017, 96, 598-609.	1.9	34
11	Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1â€OHâ€midazolam in morbidly obese and weight loss surgery patients. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 20-30.	1.3	30
12	Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions. AAPS Journal, 2016, 18, 321-332.	2.2	30
13	Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. European Journal of Pharmaceutical Sciences, 2015, 67, 32-44.	1.9	29
14	What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing. AAPS Journal, 2019, 21, 17.	2.2	29
15	Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models. Journal of Pharmacy and Pharmacology, 2016, 68, 1501-1515.	1.2	28
16	IMI â€“ Oral biopharmaceutics tools project â€“ Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 50-63.	2.0	27
17	Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs. Translational Cancer Research, 2017, 6, S1512-S1529.	0.4	26
18	Drug disposition and modelling before and after gastric bypass: immediate and controlledâ€release metoprolol formulations. British Journal of Clinical Pharmacology, 2015, 80, 1021-1030.	1.1	25

#	Article	IF	Citations
19	Review article: time to revisit Childâ€Pugh score as the basis for predicting drug clearance in hepatic impairment. Alimentary Pharmacology and Therapeutics, 2021, 54, 388-401.	1.9	25
20	Implications of intercorrelation between hepatic CYP3A4â€CYP2C8 enzymes for the evaluation of drugâ€“drug interactions: a case study with repaglinide. British Journal of Clinical Pharmacology, 2018, 84, 972-986.	1.1	19
21	Towards Further Verification of Physiologically-Based Kidney Models: Predictability of the Effects of Urine-Flow and Urine-pH on Renal Clearance. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 157-168.	1.3	17
22	Accounting for inter-correlation between enzyme abundance: a simulation study to assess implications on global sensitivity analysis within physiologically-based pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 137-154.	0.8	16
23	Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue Distribution. AAPS Journal, 2020, 22, 41.	2.2	15
24	Simultaneous Assessment In Vitro of Transporter and Metabolic Processes in Hepatic Drug Clearance: Use of a Media Loss Approach. Drug Metabolism and Disposition, 2018, 46, 405-414.	1.7	13
25	Integration of advanced methods and models to study drug absorption and related processes: An UNGAP perspective. European Journal of Pharmaceutical Sciences, 2022, 172, 106100.	1.9	12
26	Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS Iâ€“IV drugs. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 27-42.	0.8	10
27	Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats. Molecular Pharmaceutics, 2021, 18, 2997-3009.	2.3	10
28	A study of the dosage and duration for levobupivacaine infusion by the caudalâ€epidural route in infants aged 3â€6 months. Paediatric Anaesthesia, 2019, 29, 161-168.	0.6	8
29	Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series. Pharmaceutics, 2022, 14, 1010.	2.0	7
30	The Impact of Formulation, Delivery, and Dosing Regimen on the Risk of Drugâ€“Drug Interactions. Clinical Pharmacology and Therapeutics, 2019, 105, 1329-1331.	2.3	6
31	The nested enzyme-within-enterocyte (NEWE) turnover model for predicting dynamic drug and disease effects on the gut wall. European Journal of Pharmaceutical Sciences, 2019, 131, 195-207.	1.9	5
32	Physiologically-Based Pharmacokinetics. , 2011, , 361-386.		4
33	USING PAGERANK AND SOCIAL NETWORK ANALYSIS TO SPECIFY MENTAL HEALTH FACTORS. Proceedings of the Design Society, 2021, 1, 3379-3388.	0.5	4
34	Serious Gaming of Logistics Management in Pediatric Emergency Medicine. International Journal of Serious Games, 2020, 7, 47-77.	0.8	4
35	A latent variable approach to account for correlated inputs in global sensitivity analysis. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 671-686.	0.8	2
36	Application of the Nested Enzymeâ€Withinâ€Enterocyte (NEWE) Turnover Model for Predicting the Time Course of Pharmacodynamic Effects. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 617-627.	1.3	1

#	Article	IF	Citations
37	Can We Rationalize Oral Drug Exposure Following Bariatric Surgery to Meet the Pharmacotherapeutic Needs of a Growing Patient Population? Commentary on: â€œLithium Toxicity Following Roux-en-Y Gastric Bypassâ€• Bariatric Surgical Patient Care, 2014, 9, 81-83.	0.1	0
38	Ratifying the dosage and duration of levo-bupivacaine infusion by the caudal-epidural route in infants aged three to six months. British Journal of Anaesthesia, 2018, 120, e11-e12.	1.5	0
39	Simulation and Model Validation for Mental Health Factors Using a Multi-Methodology Hybrid Approach. , 2021, , .		0